Immediate Impact
9 standout
Citing Papers
Annual review of PROTAC degraders as anticancer agents in 2022
2024 Standout
Management of chronic myeloid leukemia in 2023 – common ground and common sense
2023 Standout
Works of Laura Stenson being referenced
Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial
2020
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Laura Stenson | 2 | 37 | 32 | 16 | 4 | 45 | |
| T. Karrison | 21 | 12 | 9 | 6 | 38 | ||
| Laurent Garderet | 42 | 24 | 4 | 4 | 45 | ||
| Benedetta Cambò | 27 | 17 | 13 | 5 | 44 | ||
| Olivia Chandesris | 27 | 18 | 11 | 4 | 52 | ||
| Pietro Perini | 1 | 22 | 24 | 6 | 4 | 40 | |
| Aaron Ronson | 25 | 11 | 26 | 5 | 168 | ||
| Mary-Anne Kedda | 1 | 50 | 32 | 13 | 5 | 171 | |
| Raphael Isaacs | 1 | 23 | 20 | 7 | 3 | 45 | |
| W. Charles | 17 | 20 | 7 | 4 | 52 | ||
| Kim‐Hien T. Dao | 1 | 49 | 47 | 13 | 4 | 63 |
All Works
Loading papers...